3.115
price down icon8.52%   -0.29
after-market Handel nachbörslich: 3.17 0.055 +1.77%
loading
Schlusskurs vom Vortag:
$3.405
Offen:
$3.34
24-Stunden-Volumen:
1.61M
Relative Volume:
0.70
Marktkapitalisierung:
$241.39M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-1.0247
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
-27.89%
1M Leistung:
-41.34%
6M Leistung:
-52.66%
1J Leistung:
-74.84%
1-Tages-Spanne:
Value
$3.06
$3.40
1-Wochen-Bereich:
Value
$3.06
$4.05
52-Wochen-Spanne:
Value
$2.88
$12.51

Solid Biosciences Inc Stock (SLDB) Company Profile

Name
Firmenname
Solid Biosciences Inc
Name
Telefon
617-337-4680
Name
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Name
Mitarbeiter
100
Name
Twitter
@SolidBioDMD
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
SLDB's Discussions on Twitter

Vergleichen Sie SLDB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SLDB
Solid Biosciences Inc
3.115 241.39M 14.79M -102.44M -91.73M -3.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-08 Eingeleitet Truist Buy
2024-12-13 Eingeleitet Wedbush Outperform
2024-12-10 Eingeleitet JMP Securities Mkt Outperform
2024-07-15 Hochstufung JP Morgan Neutral → Overweight
2024-06-24 Hochstufung Leerink Partners Market Perform → Outperform
2024-05-31 Fortgesetzt Piper Sandler Overweight
2024-03-28 Eingeleitet William Blair Outperform
2024-03-15 Eingeleitet Citigroup Buy
2024-03-14 Hochstufung Piper Sandler Neutral → Overweight
2023-12-08 Eingeleitet H.C. Wainwright Buy
2021-07-12 Eingeleitet Piper Sandler Neutral
2021-05-27 Eingeleitet Jefferies Buy
2021-03-16 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-03-09 Eingeleitet Barclays Overweight
2021-01-08 Hochstufung Credit Suisse Underperform → Neutral
2020-07-28 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-05-07 Herabstufung Evercore ISI Outperform → In-line
2019-10-11 Eingeleitet Evercore ISI Outperform
2019-08-29 Herabstufung Citigroup Neutral → Sell
2019-08-19 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-08-16 Hochstufung Chardan Capital Markets Neutral → Buy
2019-05-14 Herabstufung Credit Suisse Neutral → Underperform
2019-05-14 Herabstufung Goldman Neutral → Sell
2019-02-08 Hochstufung Citigroup Sell → Neutral
2019-02-08 Herabstufung SVB Leerink Outperform → Mkt Perform
2018-11-06 Eingeleitet Citigroup Sell
2018-09-06 Eingeleitet Credit Suisse Neutral
Alle ansehen

Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten

pulisher
Apr 01, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan

Apr 01, 2025
pulisher
Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail

Mar 20, 2025
pulisher
Mar 19, 2025

Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st

Mar 19, 2025
pulisher
Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 14, 2025

Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey

Mar 14, 2025
pulisher
Mar 13, 2025

Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Solid Biosciences director Kahn Clare buys $9,924 in stock By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Solid Biosciences’ SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Q1 EPS Forecast for Solid Biosciences Boosted by Analyst - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Top 10 Insider Purchases Last Month - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewswire

Mar 12, 2025
pulisher
Mar 12, 2025

Solid Biosciences Inc. to Present Phase 1/2 INSPIRE DUCHENNE Trial Data on SGT-003 Gene Therapy for Duchenne Muscular Dystrophy at 2025 MDA Conference - Nasdaq

Mar 12, 2025
pulisher
Mar 12, 2025

Breakthrough DMD Gene Therapy Results: Solid Bio Reveals INSPIRE Trial Data at Major Conference - StockTitan

Mar 12, 2025
pulisher
Mar 11, 2025

Solid Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Solid Biosciences Inc. (NASDAQ:SLDB) Shares Acquired by Rhumbline Advisers - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

HC Wainwright Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Solid Biosciences shares leap on raised price target to $20 By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Solid Biosciences price target raised to $20 from $16 at H.C. Wainwright - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

FY2026 Earnings Forecast for SLDB Issued By William Blair - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Chardan Capital Reaffirms “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

SLDB Stock Rallies 60% in a Month: Here's What You Should Know - MSN

Mar 07, 2025
pulisher
Mar 07, 2025

Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

Solid Biosciences Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView

Mar 07, 2025
pulisher
Mar 07, 2025

Solid Biosciences stock target holds at $15 on therapy optimism - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Pipeline Expansion Justify Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Solid Biosciences stock target holds at $15 on therapy optimism By Investing.com - Investing.com UK

Mar 07, 2025
pulisher
Mar 07, 2025

Solid Biosciences: Positive DMD Program Developments and Strong Financial Position Justify Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 07, 2025
pulisher
Mar 06, 2025

Solid Biosciences Inc. (SLDB) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 06, 2025

Solid Biosciences reports Q4 EPS ($1.00), consensus (78c) - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Solid Biosciences Reports Positive Data from Duchenne Gene Therapy Trial and Provides Business Update - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Solid Biosciences Inc. SEC 10-K Report - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

SLDBSolid Bioscience Latest Stock News & Market Updates - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

Duchenne Patient Stories - Solid Biosciences

Mar 05, 2025
pulisher
Mar 05, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Genetic Medicine Developer Solid Biosciences Sets March Conference Schedule: What's Coming? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

How Solid Biosciences Uses Equity Compensation to Attract New Talent - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey

Mar 04, 2025
pulisher
Mar 03, 2025

3 Reasons to Sell CSL and 1 Stock to Buy Instead - The Globe and Mail

Mar 03, 2025
pulisher
Mar 01, 2025

Solid Biosciences Inc. (SLDB) Latest Stock News & Headlines - Yahoo Canada Finance

Mar 01, 2025
pulisher
Feb 28, 2025

Leerink Partnrs Issues Optimistic Outlook for SLDB Earnings - MarketBeat

Feb 28, 2025

Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Solid Biosciences Inc-Aktie (SLDB) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Bain Capital Life Sciences Inv
10% Owner
Feb 19 '25
Buy
4.03
1,000,000
4,030,000
5,034,582
PERCEPTIVE ADVISORS LLC
Director
Feb 19 '25
Buy
4.03
5,000,000
20,150,000
11,833,539
Adage Capital Management, L.P.
10% Owner
Feb 18 '25
Buy
7.56
252,545
1,909,240
4,248,084
Hanrahan Jessie
Chief Regulatory Officer
Feb 14 '25
Sale
3.96
3,079
12,193
19,281
Brooks Gabriel
Chief Medical Officer
Feb 14 '25
Sale
3.96
3,256
12,894
22,812
Tan Kevin
CFO & Treasurer
Feb 14 '25
Sale
3.96
3,164
12,529
32,250
Howton David T
Chief Operating Officer
Feb 14 '25
Sale
3.96
5,561
22,022
24,789
Herzich Paul
Chief Technology Officer
Feb 14 '25
Sale
3.96
2,688
10,644
18,388
Cumbo Alexander
President and CEO
Feb 14 '25
Sale
3.96
11,365
45,005
60,717
Ganot Ilan
Director
Feb 14 '25
Sale
3.96
1,711
6,776
14,839
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):